Core Insights - Voyager Therapeutics anticipates 2026 to be a transformative year, focusing on tau-targeting assets for Alzheimer's disease, novel I.V.-delivered neuro gene therapies, and the advancement of its nonviral delivery platform, Voyager NeuroShuttle [2][4] Financial Position - As of December 31, 2025, Voyager reported a cash position of $201.7 million, which is expected to sustain operations into 2028 [7][8] - Collaboration revenue for Q4 2025 was $15.3 million, up from $6.3 million in Q4 2024, while total collaboration revenue for the year was $40.4 million, down from $80.0 million in 2024 [12][20] Research and Development Highlights - The company expects to complete a GLP toxicology study for VY1706 in Q1 2026, with an IND application submission planned for Q2 2026 and first-in-human dosing anticipated in H2 2026 [5][6] - VY7523's clinical trial for Alzheimer's disease completed enrollment in Q4 2025, with tau PET imaging data expected in H2 2026 [6][12] Partnerships and Collaborations - Neurocrine plans to initiate a clinical trial with NBIB-'223 for Friedreich's ataxia in H2 2026, pending FDA IND clearance [6] - Voyager's partnership with Novartis for Huntington's disease and spinal muscular atrophy continues to advance [6] Pipeline Updates - Voyager has paused development of its apolipoprotein E gene therapy program to prioritize more advanced programs, despite demonstrating promising results in murine studies [5][6] - The Voyager NeuroShuttle platform has shown sustained brain exposure in a proof-of-concept study, indicating potential for high brain penetration with genetic medicines [5][6]

Summary of Voyager Therapeutics FY Conference Call Company Overview - **Company**: Voyager Therapeutics (NasdaqGS: VYGR) - **Industry**: Biotechnology, specifically focusing on gene therapy and treatments for neurodegenerative diseases, particularly Alzheimer's disease Key Points 1. Strategic Focus Areas - **Three Pillars of Value**: - **Tau Target**: Focus on tau as a target for Alzheimer's with two programs: VY7523 (anti-tau antibody) and VY-1706 (gene therapy) [2][3] - **Gene Therapy**: Plans to advance two gene therapy assets into clinical trials, one in partnership with Neurocrine and one wholly owned by Voyager [2] - **NeuroShuttle Platform**: Development of a platform to deliver various drugs across the blood-brain barrier [3] 2. Tau as a Target for Alzheimer's - **Importance of Tau**: The spread of tau in the brain correlates more closely with clinical decline in Alzheimer's than amyloid accumulation [6] - **Recent Developments**: Upcoming data from J&J and Biogen on tau-targeting therapies will provide further validation for tau as a target [5][6] - **Mixed Results from Competitors**: UCB's bepranemab showed some effect on tau spread but failed to meet primary clinical endpoints, indicating the complexity of targeting tau [8][9] 3. Clinical Development Insights - **VY7523**: Preliminary safety data shows a favorable profile, with a brain-to-plasma ratio of 0.3% and a half-life supporting monthly dosing [20] - **MAD Study Design**: The multiple ascending dose (MAD) study is designed to assess the effect on tau PET imaging, which is the key biomarker for evaluating the spread of pathological tau [21] - **Future Studies**: Plans to include tau PET imaging data in future studies and emphasize its importance over fluid-based biomarkers [24][25] 4. Gene Therapy Developments - **VY-1706**: Aiming for a 50%-70% reduction in tau mRNA/protein, with a focus on lower doses to enhance safety and reduce costs [31] - **FDA Interactions**: Productive discussions with the FDA regarding trial designs and plans to file an IND in Q2 2026 [33] 5. NeuroShuttle Platform - **Differentiation**: The ALPL shuttle shows longer half-life and no adverse effects on reticulocyte counts compared to transferrin receptor shuttles, making it a promising delivery method for various therapies [46] - **Therapeutic Modalities**: Exploring antibodies, peptides, and oligonucleotides for use with the NeuroShuttle platform [47] 6. Partnerships and Collaborations - **Neurocrine Partnership**: Progress on gene therapy programs, including FA and GBA1, with plans to enter the clinic this year [48] 7. Market Opportunities - **Alzheimer's Disease**: The potential for anti-tau therapies to be used in combination with anti-amyloid treatments, especially for patients who do not respond to the latter [41] - **Broader Applications**: Potential to address other tauopathies beyond Alzheimer's, expanding the market opportunities for Voyager's therapies [42] Additional Insights - **Clinical Predictions**: Anticipation that BIIB080 will show significant effects in clinical measures, which could influence Voyager's approach to VY-1706 [36] - **Patient Population**: Targeting early Alzheimer's patients for clinical trials, aligning with trends in the amyloid treatment landscape [26][27] This summary encapsulates the key discussions and insights from the Voyager Therapeutics FY Conference, highlighting the company's strategic focus, clinical developments, and market opportunities in the biotechnology sector.

Core Insights - Voyager Therapeutics is expanding its Alzheimer's disease franchise with a new program targeting apolipoprotein E (APOE), specifically modulating the expression of the high-risk APOE4 variant while delivering the protective APOE2 variant [1][5][6] - The TRACER capsid platform is utilized for intravenous delivery, allowing the bifunctional payload to effectively cross the blood-brain barrier and target relevant brain regions [2][4] - The company aims to leverage its expertise in Alzheimer's biology to advance multiple therapeutic targets, including tau, amyloid, and APOE, to improve patient outcomes [3][5] Company Overview - Voyager Therapeutics is a biotechnology firm focused on using human genetics to treat neurological diseases, with a pipeline that includes programs for Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) [5][7] - The company's Alzheimer's disease franchise now includes four wholly-owned assets, including the anti-tau antibody VY7523 and gene therapies targeting tau, amyloid, and APOE [3][5][6] Research and Development - Preclinical studies demonstrated that a single intravenous injection of the TRACER capsid significantly reduced endogenous APOE4 levels while increasing APOE2 expression in relevant brain regions [2][6] - VY7523 is currently in a multiple ascending dose clinical trial, with initial tau PET data expected in the second half of 2026 [6] - VY1706, a tau silencing gene therapy, has shown up to 73% knockdown of tau mRNA in non-human primates and is advancing towards IND in 2026 [6] Technology Platform - The TRACER capsid discovery platform enables rapid identification of novel AAV capsids for gene therapy, facilitating effective delivery across the central nervous system [4][7] - The platform has been validated in cross-species preclinical studies, demonstrating widespread payload expression in the CNS at low doses [4][7]

Core Insights - Voyager Therapeutics reported a strong cash position of $295 million, expected to last until mid-2027, excluding potential milestone payments from partnerships [2][8] - The company is advancing its pipeline, particularly focusing on tau-targeting programs for Alzheimer's disease, with IND submissions anticipated in 2026 [2][5] Financial Results - Collaboration revenue for Q1 2025 was $6.5 million, down from $19.5 million in Q1 2024, primarily due to decreased revenue from Neurocrine collaboration [14] - Net loss for Q1 2025 was $31.0 million, compared to $11.3 million in Q1 2024, attributed to lower collaboration revenue and increased operating expenses [14][19] - Research and development expenses increased to $31.5 million in Q1 2025 from $27.1 million in Q1 2024, driven by higher program-related spending [14][19] Pipeline and Development Updates - The tau silencing gene therapy VY1706 demonstrated up to 73% knockdown of tau mRNA in non-human primates after a single intravenous dose [5] - The company is preparing for IND submissions for VY1706 and the Neurocrine-partnered Friedreich's ataxia and GBA1 programs in 2026 [6][14] - Voyager's anti-tau antibody VY7523 is currently in a multiple ascending dose clinical trial for Alzheimer's Disease, with initial tau PET data expected in the second half of 2026 [6][14] Upcoming Milestones - Multiple presentations at the ASGCT 2025 annual meeting are planned, including data on VY1706 and VY7523 [5][6] - The initiation of clinical trials for the FA and GBA1 programs is expected in 2026, with potential milestone payments totaling $35 million [6][14]

Core Insights - Voyager Therapeutics is advancing two preclinical programs targeting tau for Alzheimer's disease treatment, specifically the tau silencing gene therapy VY1706 and the anti-tau antibody VY7523 [1][2] Group 1: VY1706 Tau Silencing Gene Therapy - A single intravenous (IV) administration of VY1706 resulted in a dose-dependent reduction of tau mRNA by 44% to 73% and tau protein by 27% to 55% in a non-human primate study, with effects sustained for up to three months [4] - The therapy demonstrated broad distribution across brain regions affected by Alzheimer's disease, including the hippocampus and frontal cortex, while liver targeting was reduced by approximately 30-fold compared to wild type AAV9 [4][8] - VY1706 is currently in Investigational New Drug (IND)-enabling studies, with an IND filing anticipated in 2026 [4][8] Group 2: VY7523 Anti-Tau Antibody - Preclinical data indicate that the murine version of VY7523 selectively binds to pathological tau tangles and effectively reduces tau spread in a P301S mouse model [5][9] - VY7523 has shown approximately 70% inhibition of pathological tau spread in preclinical studies and is currently being evaluated in a multiple ascending dose trial for early Alzheimer's disease patients [9] - Initial tau positron emission tomography (PET) imaging data for VY7523 is expected in the second half of 2026 [5][9] Group 3: Upcoming Events and Presentations - Voyager will present data on both therapies at the AD/PD™ 2025 conference in Vienna from April 1-5, 2025, and will host a live webcast on April 7, 2025, to recap key findings [1][7] - Dr. Toby Ferguson, Chief Medical Officer, will participate in two panels discussing anti-tau therapies and drug development challenges at the conference [6]